New York (dpa-Afx)-After a gratifying stock exchange week, the US stock markets went out of store on Friday with slight profits. Skeptic tones from the semiconductor group Intel hardly clouded the picture in the technology sector. In terms of reporting season, not much happened on the last trading day of the week. The hope of a conciliatory customs cleaning between the United States and the European Union supported the market.
The Dow Jones Industrial closed with an increase of 0.47 percent at 44,901.92 points. This resulted in a weekly profit of around 1.3 percent for the Wall Street Leindex. The market width S&P 500 climbed a record high on Friday and ultimately won 0.40 percent to 6,388.64 points. The Nasdaq 100 also reached a record and in the end increased by 0.23 percent to 23,272.25 points.
In the United States, the orders for long -lasting goods did not drop as much as feared in June. Orders fell by 9.3 percent in the month comparison, as the US Ministry of Trade announced in Washington on Friday, according to an initial estimate. Economists had expected an average of 10.7 percent. However, the orders had increased by 16.5 percent in the previous month.
The turnover of the battered chip group Intel stagnated in the year. The bottom line was that there was a loss of $ 2.9 billion after red numbers of $ 1.6 billion a year earlier. The group admitted that it could drop the development of its modern processor technology 14a if there was no enough customers. So there are question marks behind the U -turn. The Intel papers lost 8.5 percent.
It caught the titles of Charter Communications (Charter A) even worse. They collapsed by a good 18 percent after the cable network operator had lost more internet customers than expected in the second quarter. In this context, the company spoke of increasing pressure through the 5G and fiber optic internet offers of the mobile phone competitors.
For Sarepta Therapeutics’s shares, it went down by 7.4 percent after the European supervisory authorities had rejected gene therapy Elevidys. This exacerbates the drug manufacturer’s crisis after the delivery of this medication has already been banned in the USA. While Sarepta markets therapy in the United States, Roche holds the rights outside of the USA./EDH/he